For instance, anti-DLL4 mAbs (Demcizumab) and mAbs targeting Notch 2/3 (Tarextumab) are being evaluated in pre-clinical and in early phase clinical settings for their safety and therapeutic effects in solid tumors including of the breast, demonstrating initial evidence for anti-tumor activity and/or disease stabilization [8,129,130,131]. Here, DLL4 is linked to neoplasm.